Evidence Generation Solutions & Expertise to Improve Alzheimer's Disease Clinical Trials
We Have Solutions to Help Your Study Succeed
Signant Health applies decades of direct experience and deep expertise with Alzheimer’s disease, as well as innovative clinical trial technologies within our Signant SmartSignals suite, to improve the chances of success by making trial participation easier and optimizing the quality and reliability of data generated.
As the first eClinical company to develop electronic assessments for dementia trials, our mature eCOA platform provides validated electronic versions of common AD study scales such as ADAS-Cog and MMSE. Advanced features such as preset workflows, edit checks, and audio/video recording capabilities ensure scoring accuracy and consistency. When applied in conjunction with our Blinded Data Analytics, published data show a significant reduction in errors as well as increased ClinRO and endpoint data reliability.
Optimize ClinRO & Endpoint Data
Eliminate Rater Error & Variability
Our team of Alzheimer’s clinical experts qualify, train, and certify raters to ensure accurate COA scoring and administration. We perform independent reviews of audio, video and data, and recalibrate raters throughout the study as needed to maintain standards, and our technology allows for gatekeeping by qualification status to further safeguard your study data and prepare for regulatory reviews.
Increase Participant Retention in Long-Term Follow up Periods
Participating in clinical trials is difficult for people living with Alzheimer’s. Signant SmartSignals solutions simplify participation for patients and caregivers – from eConsent to Patient Concierge and Telemedicine, leverage our solutions to reduce the burden on patients and caregivers during long-term follow up studies, improving retention in these critical phases.
Increase Signal Detection Opportunities
Study teams require sensitive and accurate measures to detect signal in AD studies. Our clinical experts ensure cognitive and functional assessments are done to the highest standard. In addition, Signant’s proprietary computerized Cognitive Assessments help researchers precisely detect subtle changes in over time to understand a drug’s effect on cognitive function.
Safeguard Data Quality Throughout a Program
Reliable and accurate data is the cornerstone to any successful clinical trial but especially vital in Alzheimer’s studies which suffer extremely high failure rates. Signant’s in-study data quality monitoring and analytics solutions can identify, correct, and prevent common issues such as errors, bias, or fraud.
75
LANGUAGES
COUNTRIES
50
107,000+
PATIENTS
16,000+
SITES
STUDIES
227
I - IV
PHASES
Our Alzheimer's Disease Experience by the Numbers
Alzheimer's Research Solutions Brochure
Alzheimer's Disease Trial Solution Resources
Signant's Subject Matter Experts
Alzheimer's Trial Solutions Overview
Enhance Your Alzheimer's Disease Clinical Trials with Signant
RATER TRAINING
BLINDED DATA ANALYTICS
eCOA
CENTRAL RATINGS
LEARN MORE 🠖LEARN MORE 🠖LEARN MORE 🠖LEARN MORE 🠖
READY TO GET STARTED?
See how Signant can support your next Alzheimer's Disease clinical trial.
Alzheimer’s Disease (AD) severely impacts daily life for people living with this form of dementia, but clinical trials investigating disease-modifying treatments unfortunately suffer high failure rates. That's where Signant's unrivaled solutions and expertise can help.
